C Oliver Hanemann
Overview
Explore the profile of C Oliver Hanemann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
79
Citations
1626
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dave F, Herrera K, Lockley A, van de Weijer L, Henderson S, Sofela A, et al.
Oncogene
. 2024 Sep;
43(41):3080.
PMID: 39327460
No abstract available.
2.
Dave F, Herrera K, Lockley A, van de Weijer L, Henderson S, Sofela A, et al.
Oncogene
. 2024 Aug;
43(41):3049-3061.
PMID: 39179860
Meningioma and schwannoma are common tumours of the nervous system. They occur sporadically or as part of the hereditary NF2-related schwannomatosis syndrome. There is an unmet need for new effective...
3.
Na J, Shaji S, Hanemann C
EBioMedicine
. 2024 Jun;
105:105211.
PMID: 38917510
Background: External radiation therapy (RT) is often a primary treatment for inoperable meningiomas in the absence of established chemotherapy. Histone deacetylase 6 (HDAC6) overexpression, commonly found in cancer, is acknowledged...
4.
Wang J, Landry A, Raleigh D, Sahm F, Walsh K, Goldbrunner R, et al.
Neuro Oncol
. 2024 May;
26(10):1742-1780.
PMID: 38695575
Meningiomas are the most common primary intracranial tumors in adults and are increasing in incidence due to the aging population and increased access to neuroimaging. While most exhibit nonmalignant behavior,...
5.
Purshouse K, Bulbeck H, Rooney A, Noble K, Carruthers R, Thompson G, et al.
Neuropathol Appl Neurobiol
. 2024 Apr;
50(2):e12979.
PMID: 38605644
In 2015, a groundswell of brain tumour patient, carer and charity activism compelled the UK Minister for Life Sciences to form a brain tumour research task and finish group. This...
6.
Young C, Chaouch A, McDermott C, Al-Chalabi A, Chhetri S, Talbot K, et al.
Amyotroph Lateral Scler Frontotemporal Degener
. 2024 Mar;
25(5-6):475-485.
PMID: 38465877
Objective: Dyspnea, or breathlessness, is an important symptom in amyotrophic lateral sclerosis/motor neuron disease (ALS/MND). We examined the measurement properties of the Dyspnea-12. Methods: Rasch analysis enabled conversion of raw...
7.
Diaz L, Gil-Ranedo J, Jaworek K, Nsek N, Marques J, Costa E, et al.
EMBO Rep
. 2024 Jan;
25(1):168-197.
PMID: 38225354
Cell commitment to tumourigenesis and the onset of uncontrolled growth are critical determinants in cancer development but the early events directing tumour initiating cell (TIC) fate remain unclear. We reveal...
8.
van de Weijer L, Ercolano E, Zhang T, Shah M, Banton M, Na J, et al.
Acta Neuropathol Commun
. 2023 Dec;
11(1):198.
PMID: 38102708
Meningiomas are the most common intracranial brain tumours. These tumours are heterogeneous and encompass a wide spectrum of clinical aggressivity. Treatment options are limited to surgery and radiotherapy and have...
9.
Sundby R, Rhodes S, Komlodi-Pasztor E, Sarnoff H, Grasso V, Upadhyaya M, et al.
Clin Trials
. 2023 Oct;
21(1):40-50.
PMID: 37904489
Introduction: Neurofibromatosis 1 and schwannomatosis are characterized by potential lifelong morbidity and life-threatening complications. To date, however, diagnostic and predictive biomarkers are an unmet need in this patient population. The...
10.
Jungwirth G, Hanemann C, Dunn I, Herold-Mende C
Adv Exp Med Biol
. 2023 Jul;
1416:199-211.
PMID: 37432629
The management of clinically aggressive meningiomas remains challenging due to limited treatment options aside from surgical removal and radiotherapy. High recurrence rates and lack of effective systemic therapies contribute to...